Prostate cancer detection with multiparametric MRI: A comparison of 1 M-Concentration gadobutrol with 0.5 M-Concentration gadolinium-based contrast agents

Abstract

Introduction: Gadobutrol (Gd-DO3A-butrol) (Gadovist®) is a macrocyclic gadolinium-based contrast agent for magnetic resonance imaging (MRI) formulated at 1.0 mmol Gd/ml. Gadobutrol's higher concentration compared to other contrast agents (0.5 mmol Gd/ml) is associated with higher T1 relaxivity. We examined whether gadobutrol increases the accuracy of prostate cancer detection using dynamic contrast-enhanced MRI. Materials and Methods: Multiparametric MRI was performed in 379 patients: 94 patients received 1 M gadobutrol while 285 randomly received equivalent doses of 0.5 M gadoterate meglumine or gadopentetate dimeglumine. MRI images were retrospectively and blindly assessed for the presence of cancer by comparing them with prostate biopsy findings. Results: The specificity and accuracy were significantly higher with 1 M gadobutrol than 0.5 M of the other contrast agents. There were no significant differences in the sensitivity, or positive and negative predictive values. Conclusion: Multiparametric MRI using 1 M gadobutrol may improve the accuracy of prostate cancer detection.